Selecta Biosciences Inc (SELB): OrbiMed Advisors Reports New Stake

Page 1 of 13

Samuel Isaly’s Orbimed Advisors recently filed a Form 13D with the Securities and Exchange Commission, in which it reported a new stake in Selecta Biosciences Inc (NASDAQ:SELB). The position amasses 1.84 million shares, which account for 10.03% of the outstanding stock of the company. The filing also revealed that this acquisition of shares is solely for investment purposes and that the fund will continue to further examine its investment by monitoring the company’s business moves.

Selecta Biosciences is a clinical-stage biopharmaceutical company that works on discovering therapeutics that could help patients who suffer from a variety of serious and rare conditions. The company recently started trading on the Nasdaq, on June 23, and its shares have remained largely unchanged since then, save for a short downward blip on June 24. The company has a market cap of $250 million.

Samuel Isaly - Orbimed Advisors

You can access the original SEC filing by clicking here.

Follow Selecta Biosciences Inc

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
OrbiMed Advisors 0 1,842,797 0 1,842,797 1,842,797 10.3%
OrbiMed Capital GP III 0 1,825,415 0 1,825,415 1,825,415 10.2%
Samuel D. Isaly 0 1,842,797 0 1,842,797 1,842,797 10.3%

Follow Samuel Isaly's OrbiMed Advisors

Page 1 of 13 – SEC Filing

Washington, D.C.  20549
Under the Securities Exchange Act of 1934


(Name of Issuer)


(Title of Class of Securities)


(CUSIP Number)
OrbiMed Advisors LLC
OrbiMed Capital GP III LLC
Samuel D. Isaly
601 Lexington Avenue, 54th Floor
New York, NY 10022

Telephone:  (212) 739-6400

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)

June 27, 2016

(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of § 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box  o.
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7(b) for other parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Follow Selecta Biosciences Inc

Page 1 of 13